CoolCryoQuick and Powerful Cryoablation
Cardiac Cryoablation System
CoolCryo is a cardiac cryoablation technology that uses liquid nitrogen as the cooling medium. Liquid nitrogen is widely available, commonly used, and one of the most cost-effective cooling agents, which significantly reduces the cost of the procedure and increases its accessibility. One of the key advantages of CoolCryo is its heated, formable tip, which enables fast ablation and thus shortens the duration of the procedure.
The Problem
The Problem
Atrial fibrillation (AFib) is the most common heart rhythm disorder that causes the upper chambers of the heart to beat irregularly and often rapidly.
Uncontrolled atrial fibrillation can lead to serious complications, including stroke, heart failure, and chronic fatigue—significantly reducing quality of life. Common issues include:
- stroke risk up to 5× higher
- breathlessness, dizziness, palpitations
- other unusual symptoms that often go unnoticed
When Catheter Ablation Works — and When It May Not
- Catheter ablation is an effective treatment for atrial fibrillation (AFib) and other arrhythmias. It targets small areas of heart tissue causing abnormal signals, helping restore normal rhythm and reduce symptoms.
- Its success varies with disease stage. In advanced or long-standing AFib, results may not last. Some patients need extra treatments such as surgical ablation.
Unique design and key features
Unique design and key features
Innovative liquid nitrogen-based cryoablation system
Moldable aluminum tip for precise and faster procedures
Adjustable ablation depth via time and temperature settings
Reference (3): Based on Medinice experimental data during preclinical studies and data from other available sources.
Freezing equals freezing?
- Quick freezing - four times faster than with other devices - more efficient necrosis2
- Linear deep freezing due to coldest cryogen temperature and highest cryogen heat capacity, higher volume of lesions1
References:
- Goette, Julia, et al. "Freezing equals freezing? Performance of two cryoablation devices in concomitant mitral valve repair". The Thoracic and Cardiovascular Surgeon 64.08 (2016): 672-678.
- Baust, John G., and Andrew A. Gage. "The molecular basis of cryosurgery." BJU international 95.9 (2005).
- Based on Medinice experimental data during preclinical studies and data from other available sources.
Barriers and limitations of surgical cryoablation
Barriers and limitations of surgical cryoablation
Surgeons point to the low usability of current systems and prolonged application time. Key limitations include insufficient freezing power, difficulty cryoablating thick tissues, inability to perform ablation on a beating heart, high equipment costs, and limited access to coolant. During mitral valve surgery, 46% of surgeons report no barriers, but some cite added cross-clamp time (23%) or high patient risk (13%) as reasons preventing wider use of existing systems.
Source: Mehaffey, J. Hunter, et al. "Barriers to atrial fibrillation ablation during mitral valve surgery." The Journal of thoracic and cardiovascular surgery 165.2 (2023): 650-658.
The Solution
CoolCryo for surgical ablation
The Solution
CoolCryo for surgical ablation
At least four times faster procedure for surgical ablation
Possibility of ablating very thick tissues, potentially also the ventricle
Possibility of ablating on a beating heart
Access through sternotomy or minimally invasive methods
Patented design and functionalities
Global patent protection
Our CoolCryo technology is protected by a wide portfolio of international patents, highlighting our commitment to innovation. Patents granted in major areas such as Poland, US, Canada, China, Japan, South Korea, India, EPO, and WPO.
CoolCryo is protected by a comprehensive and wide-ranging intellectual property protection strategy. This broad protection ensures uniqueness, reliability, and competitive advantage of our technology worldwide.
Potential application of CoolCryo in ventricular tachycardia
A recent use case highlights a promising new application of CoolCryo in the treatment of ventricular tachycardia (VT). While pharmacotherapy is typically the first-line treatment for electrical storm, recurrent ventricular arrhythmias may require thoracic sympathectomy or surgical ablation, particularly when catheter-based techniques are ineffective. In patients who cannot tolerate heart arrest, beating-heart ablation is preferred; however, conventional cryoablation systems using argon or nitrous oxide often lack adequate freezing power. CoolCryo, leveraging liquid nitrogen’s superior freezing capacity, addresses these limitations by enabling effective cryoablation regardless of heart wall thickness or blood flow.Click here for more detailsClick here for more details
We Care About Your Privacy
Medinice S.A. uses cookies to improve and customize users experience on our website. By selecting 'Accept', you consent to the use of all cookies that gather and use information about your interactions with our site to provide personalized content and enhance your digital experience. Please read our Privacy Policy for more information.